Clinical Trial Update: Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Saccharomyces boulardii CNCM I-745 for irritable bowel syndrome (including IBS-D and mixed symptoms); sponsor Biocodex; the st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diarrhea-predominant Irritable Bowel Syndrome
• Irritable Bowel Syndrome
• Irritable Bowel Syndrome Mixed Symptoms

Drugs mentioned

• Saccharomyces boulardii CNCM I-745 (Saccharomyces boulardii)

Snippet

Sponsor: Biocodex | Conditions: IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant) | Phase 3 | Status: RECRUITING